Dyadic International (DYAI) Interest Expenses (2017 - 2026)
Dyadic International (DYAI) posted Interest Expenses of $101800.0 for Q1 2026, up 863.46% sequentially from -$13334.0 in Q4 2025, and down 5.01% YoY from $107173.0 in Q1 2025.
Dyadic International (DYAI) Interest Expenses (2017 - 2026) Analysis & Trends
Dyadic International has reported Interest Expenses for 10 years, with the latest figure at $101800.0 in Q1 2026.
- Quarterly Interest Expenses fell 5.01% year-over-year to $101800.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $383373.0 (down 1.81% YoY) and the FY2025 annual result came in at $19.0 million, up 7.77% from the prior year.
- Interest Expenses rose to $101800.0 in Q1 2026 per DYAI's latest filing, from -$13334.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $4.1 million in Q2 2022 and troughed at -$13334.0 in Q4 2025.
- A 5-year average of $733351.6 and a median of $111053.0 in 2024 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 1482.53% in 2025, down 108.59% in 2025.
- Over 5 years, Interest Expenses stood at $13000.0 in 2022, then soared by 4844.55% to $642791.0 in 2023, then plunged by 75.86% to $155146.0 in 2024, then tumbled by 108.59% to -$13334.0 in 2025, then jumped by 863.46% to $101800.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $101800.0, -$13334.0, and $85934.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | 64,342.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101,800.00 |
| Mar 31, 2026 | 101,800.00 |
| Dec 31, 2025 | -13,334.00 |
| Dec 31, 2025 | -13,334.00 |
| Sep 30, 2025 | 85,934.00 |
| Sep 30, 2025 | 85,934.00 |
| Jun 30, 2025 | 208,973.00 |
| Jun 30, 2025 | 208,973.00 |
| Mar 31, 2025 | 107,173.00 |
| Mar 31, 2025 | 107,173.00 |
| Dec 31, 2024 | 155,146.00 |
| Dec 31, 2024 | 155,146.00 |
| Sep 30, 2024 | 114,933.00 |
| Sep 30, 2024 | 114,933.00 |
| Jun 30, 2024 | 13,205.00 |
| Jun 30, 2024 | 13,205.00 |
| Mar 31, 2024 | 21,639.00 |
| Mar 31, 2024 | 21,639.00 |
| Mar 31, 2023 | 642,791.00 |
| Mar 31, 2023 | 642,791.00 |